Arvinas, Inc. (NASDAQ:ARVN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Arvinas, Inc. (NASDAQ:ARVN) have received an average recommendation of “Moderate Buy” from the sixteen ratings firms that are covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 1 year price target among analysts that have covered the stock in the last year is $34.33.

Several equities research analysts recently commented on ARVN shares. The Goldman Sachs Group cut their price objective on shares of Arvinas from $15.00 to $12.00 and set a “neutral” rating on the stock in a research report on Thursday, April 17th. Bank of America cut their price target on Arvinas from $54.00 to $28.00 and set a “buy” rating on the stock in a report on Wednesday, March 12th. Wedbush cut Arvinas from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $57.00 to $12.00 in a research report on Wednesday, March 12th. Morgan Stanley dropped their target price on Arvinas from $48.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday, March 13th. Finally, BMO Capital Markets set a $20.00 price target on Arvinas and gave the stock an “outperform” rating in a research report on Wednesday, March 12th.

Arvinas Price Performance

Shares of Arvinas stock opened at $9.62 on Thursday. The company has a market capitalization of $661.59 million, a P/E ratio of -3.47 and a beta of 2.30. The business has a 50-day moving average of $10.05 and a two-hundred day moving average of $17.76. Arvinas has a 1 year low of $5.94 and a 1 year high of $37.38.

Arvinas (NASDAQ:ARVN) last posted its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same quarter in the previous year, the business posted ($2.53) earnings per share. On average, equities analysts anticipate that Arvinas will post -3.81 EPS for the current fiscal year.

Insiders Place Their Bets

In other Arvinas news, CEO John G. Houston sold 31,338 shares of the company’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.72, for a total value of $523,971.36. Following the transaction, the chief executive officer now directly owns 1,157,480 shares in the company, valued at $19,353,065.60. The trade was a 2.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Noah Berkowitz sold 8,658 shares of the firm’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total transaction of $74,372.22. Following the sale, the insider now owns 110,023 shares of the company’s stock, valued at $945,097.57. This trade represents a 7.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 50,230 shares of company stock valued at $769,402 over the last 90 days. 5.23% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Arvinas

A number of hedge funds and other institutional investors have recently modified their holdings of the company. GF Fund Management CO. LTD. bought a new stake in Arvinas in the 4th quarter valued at about $28,000. KBC Group NV boosted its stake in shares of Arvinas by 77.0% in the fourth quarter. KBC Group NV now owns 2,885 shares of the company’s stock valued at $55,000 after buying an additional 1,255 shares during the period. GAMMA Investing LLC boosted its stake in shares of Arvinas by 11,283.8% in the first quarter. GAMMA Investing LLC now owns 4,212 shares of the company’s stock valued at $300,000 after buying an additional 4,175 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in Arvinas during the fourth quarter worth approximately $171,000. Finally, Allspring Global Investments Holdings LLC bought a new position in Arvinas during the 1st quarter worth $80,000. Institutional investors and hedge funds own 95.19% of the company’s stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.